


PHARMACEUTICAL 2017

F-star Therapeutics Inc. Rank 186 of 313







PHARMACEUTICAL 2017

F-star Therapeutics Inc. Rank 186 of 313



The relative strengths and weaknesses of F-star Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of F-star Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 165% points. The greatest weakness of F-star Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 160% points.

The company's Economic Capital Ratio, given in the ranking table, is -282%, being 135% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	25,570
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,501
Liabilities, Non-Current	27
Other Assets	787
Other Compr. Net Income	11
Other Expenses	-1,942
Other Liabilities	6,333
Other Net Income	448
Property and Equipment	522
Research and Development	14,017
Revenues	0
Selling, General and Administrative Expense	5,739

Output Variable	Value in 1000 USD
Assets	26,879
Liabilities	9,861
Expenses	17,814
Stockholders Equity	17,018
Net Income	-17,366
Comprehensive Net Income	-17,360
Economic Capital Ratio	-282%